The Oncotype DX Breast Recurrence Score® test
The Oncotype DX Breast Recurrence Score® test provides a genomic-based, comprehensive, individualized risk assessment for early-stage invasive breast cancer in adjuvant and neoadjuvant settings. The test provides valuable information you can use to personalize a treatment plan specifically for each patient’s situation—including risk of distant recurrence, the benefit from chemotherapy and whether your patient can be treated effectively with hormonal therapy alone. 1-6
The Breast Recurrence Score® is proven to predict the likely benefit of chemotherapy 2,3,5,6 as well as the risk of distant recurrence 1,4 for patients who are newly diagnosed with early-stage invasive breast cancer. Eligible patients are diagnosed with early stage, ER+, HER2- breast cancer with either node-negative or node-positive disease. The test uses RT-PCR to measure the expression of 21 genes: 16 cancer-related genes and five reference genes - in a tumor sample after it has been removed by surgery or biopsy.
The results are presented as a quantitative score, on a scale from 0-100. The score reflects individual tumor biology—the higher the score, the higher the risk of distant recurrence and the higher the likelihood of chemotherapy benefit for that patient. 2 The Recurrence Score® result can serve as a reference point for all members of the treatment team and can make discussing treatment options with your patients easier and more efficient.
For further information, please go to oncotypeiq.com/en
REFERENCES
1. Paik et al. N Engl J Med. 2004.
2. Paik et al. J Clin Oncol. 2006.
3. Albain et al. Lancet Oncol. 2010.
4. Dowsett et al. J Clin Oncol. 2010.
5. Sparano JA et al. N Engl J Med. 2018.
6. Kalinsky et al, SABCS 2020 GS3-00
The Breast Recurrence Score® is proven to predict the likely benefit of chemotherapy 2,3,5,6 as well as the risk of distant recurrence 1,4 for patients who are newly diagnosed with early-stage invasive breast cancer. Eligible patients are diagnosed with early stage, ER+, HER2- breast cancer with either node-negative or node-positive disease. The test uses RT-PCR to measure the expression of 21 genes: 16 cancer-related genes and five reference genes - in a tumor sample after it has been removed by surgery or biopsy.
The results are presented as a quantitative score, on a scale from 0-100. The score reflects individual tumor biology—the higher the score, the higher the risk of distant recurrence and the higher the likelihood of chemotherapy benefit for that patient. 2 The Recurrence Score® result can serve as a reference point for all members of the treatment team and can make discussing treatment options with your patients easier and more efficient.
For further information, please go to oncotypeiq.com/en
REFERENCES
1. Paik et al. N Engl J Med. 2004.
2. Paik et al. J Clin Oncol. 2006.
3. Albain et al. Lancet Oncol. 2010.
4. Dowsett et al. J Clin Oncol. 2010.
5. Sparano JA et al. N Engl J Med. 2018.
6. Kalinsky et al, SABCS 2020 GS3-00
Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Genomic Prostate Score, GPS, Recurrence Score, Colon Recurrence Score, and Genomic Prostate Score are trademarks or registered trademarks of Genomic Health, Inc. Used under license.